RFI Novel Antimalarial Drug Targets
SAM.GOV Due: May 19, 2025 at 02:00 PM UTC
In-Active Sources Sought Source Url

Summary

The RFI for Novel Antimalarial Drug Targets is a market research initiative issued by the Walter Reed Army Institute of Research (WRAIR) aimed at gathering information from potential contractors who possess the expertise and capabilities to conduct research and development in the field of antimalarial drug discovery. The project focuses on investigating novel drug targets through affinity-based pulldowns, requiring specialized knowledge in chemistry, particularly related to the compound WR936909 and its structure-activity relationship (SAR). The anticipated period of performance for this study is two years, commencing on September 30, 2025, and concluding on September 29, 2027. Contractors with a background in biotechnology research and development, particularly those experienced in chemical synthesis, proteomic analysis, and laboratory operations, are encouraged to respond to this RFI. It is important to note that this is not a solicitation for proposals but rather a request for capability statements to inform future procurement actions.
Description

This Request for Information (RFI)/Sources Sought (SS) Notice is for market research information and planning purposes only, and shall not be construed as a solicitation or as an obligation on the part of WRAIR, CIDR, VDB, or the Defense Health Agency (DHA) US Army Medical Research Acquisition Ac

Entities
DOD
Department of Defense
DHA(
Defense Health Agency
NAICS
541714
Set Aside
None
Place of Performance
Point of Contact
Full Name Email Phone Type
Jaclyn Svincek [email protected] 3016192189 primary
Jennifer Jackson [email protected] secondary
Attachments
  • A03+Request+for+Information.pdf